Navigation Links
Keryx Biopharmaceuticals, Inc. To Present at the Rodman & Renshaw Annual Global Investment Conference and To Hold Investor/Analyst Day
Date:8/31/2009

nt (SPA), pending commencement. Keryx is also developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, and Keryx is in the process of finalizing the U.S. Phase 3 program for Zerenex in consultation with the FDA. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: There can be no assurance that the Company will complete cost-effective clinical trials or meet the projected development timelines for the drug candidates in its pipeline, including KRX-0401 and Zerenex; that the Company will be able to raise additional capital in the future in order to fund its operations; or that the Company's stock will not be affected by other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Keryx Biopharmaceuticals Settles License Dispute With Alfa Wassermann
2. Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Multiple Myeloma
3. Keryx Biopharmaceuticals Inc. Regains Compliance With NASDAQ Listing Requirements
4. Keryx Biopharmaceuticals, Inc. Receives Extension for Nasdaq Listing Compliance
5. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
6. Keryx Biopharmaceuticals, Inc. Requests an Appeal Hearing After Receiving Notice of Delisting From Nasdaq
7. Keryx Biopharmaceuticals Receives Nasdaq Notification
8. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2008 Financial Results
9. Keryx Biopharmaceuticals KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2008 Financial Results on Tuesday, November 11, at 8:30 A.M. EST
11. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2014)... New York (PRWEB) July 26, 2014 ... filed in state and federal litigations since the 2012 ... has surpassed 3,700 filings, Bernstein Liebhard LLP reports. According ... at least 2,064 cases have been filed in the ... Rejuvenate Hip Stem and the ABG II Modular Hip ...
(Date:7/26/2014)... 26, 2014 “Today, we introduce our ... clients all over the world. All these models are ... designed for the UK market,” says the CEO of ... suppliers of women’s special occasion outfits. , Ladies have ... comes. DressesOnlineShops.co.uk is one of the best choices for ...
(Date:7/26/2014)... “BRIC Sinuscopes Market Outlook to 2020,? provides ... report provides value, in millions of US dollars, volume ... market segments – Rigid Non-Video Sinuscopes. , The report ... each of these market categories, and global corporate-level profiles ... and deals related to the Sinuscopes market wherever available. ...
(Date:7/26/2014)... According to the Tinnitus ... this is a comprehensive guide that consists ... all types of disorders related to ... due to Ménière's disease ,     Objective ... tinnitus ,     Inner, middle or external ...
(Date:7/26/2014)... New York, New York (PRWEB) July 26, 2014 ... continue to be filed in U.S. courts, Bernstein ... calling on federal health regulators to ban uterine morcellation. ... individuals include a 46-year-old mother of four from California ... of uterine cancer called leiomyosarcoma just 10 days after ...
Breaking Medicine News(10 mins):Health News:Stryker Hip Lawsuit Filings in State and Federal Litigations Continue to Rise, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit Filings in State and Federal Litigations Continue to Rise, Bernstein Liebhard LLP Reports 3Health News:Famous Supplier DressesOnlineShops.co.uk Announces Its New Selection of Prom Dresses for the UK Market 2Health News:Sinuscopes Market in BRIC (Brazil, Russia, India & China) Forecast to 2020 Report Available at MarketOptimizer.org 2Health News:Sinuscopes Market in BRIC (Brazil, Russia, India & China) Forecast to 2020 Report Available at MarketOptimizer.org 3Health News:Sinuscopes Market in BRIC (Brazil, Russia, India & China) Forecast to 2020 Report Available at MarketOptimizer.org 4Health News:Tinnitus Miracle Book Review Exposes Thomas Coleman's Guide for Treating Tinnitus – Vkool.com 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes New Calls for Ban on Uterine Mocellation In Light of Cancer Risk 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes New Calls for Ban on Uterine Mocellation In Light of Cancer Risk 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes New Calls for Ban on Uterine Mocellation In Light of Cancer Risk 4
... Inc. (Nasdaq: ISTA ), today announced it has ... that the Dermatologic and Ophthalmic Drugs Advisory Committee will review ... on June 26, 2009. , , On November 13, ... FDA for Bepreve as an eye drop treatment for ocular ...
... increase collaboration and resource-sharing in global PD scientific community ... The Michael J. Fox Foundation for Parkinson,s Research announced ... a resource-rich virtual workplace that MJFF hopes will become ... collaborating and conversing across the globe. MJFF,s goal in ...
... by any other name is still a rose, but ... ,athlete, and ,jock, are sometimes used interchangeably, but they ... University at Buffalo researcher Kathleen E. Miller, Ph.D. "In ... gender norms, these two identities represent very different perspectives ...
... Aon Affinity , a subsidiary of Aon Corporation ... Organization has launched the NSO Marketplace(SM) to offer ... insurance, risk management, professional and personal needs of the nursing community. For ... professional liability insurance to over 675,000 nurses in the ...
... method could boost survival, German study shows , ... approach to performing radical hysterectomy in early-stage cervical ... and local tumor recurrence, a German study shows. ... is a modified version of traditional radical hysterectomy. ...
... , Complimentary Continuing Education Lectures for Healthcare Professionals , ... is a challenging diagnosis which carries a poor prognosis ... several critical signaling and tumor suppressor pathways. While current ... improving outcomes for patients. In order to do this, ...
Cached Medicine News:Health News:ISTA Pharmaceuticals Announces FDA Advisory Committee to Review Bepreve(TM) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis 2Health News:ISTA Pharmaceuticals Announces FDA Advisory Committee to Review Bepreve(TM) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis 3Health News:Michael J. Fox Foundation Announces Launch of PD Online Research 2Health News:Michael J. Fox Foundation Announces Launch of PD Online Research 3Health News:Don't mistake an athlete for a 'toxic jock' 2Health News:Exclusive Marketplace for Nursing Professionals Launched by Nurses Service Organization 2Health News:Exclusive Marketplace for Nursing Professionals Launched by Nurses Service Organization 3Health News:Adult Glioblastoma: Best Approaches to a Challenging Diagnosis 2
(Date:7/25/2014)... Research and Markets has announced ... Market 2014-2018" report to their offering. ... Diagnostic Device An ophthalmic diagnostic device ... or deficiency in the human visual pathway. Ophthalmic devices ... presbyopia, cataracts, glaucoma, retinal disorders, conjunctivitis, and dry eyes. ...
(Date:7/25/2014)... July 25, 2014 Leading events organizer ... returning for the seventh year to São Paulo, ... August 2014. The event will co-locate with Food Ingredients ... most comprehensive meeting point for the pharmaceutical industry. ... countries for pharmaceutical sales are now exploring the ...
(Date:7/24/2014)... Calif. , July 24, 2014   AcelRx ... pharmaceutical company focused on the development and commercialization of ... pain, today confirmed the PDUFA date for Zalviso remains ... that a rumor circulated online stating the Food and ... 24, 2014 there has been no notification to the ...
Breaking Medicine Technology:Global Ophthalmic Diagnostic Devices Market 2014-2018: Key Vendors are Alcon, Carl Zeiss, Haag-Streit and Topcon 2CPhI South America 2014 Launches with Generics Showing Huge Growth 2CPhI South America 2014 Launches with Generics Showing Huge Growth 3CPhI South America 2014 Launches with Generics Showing Huge Growth 4AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso 2
... Reportlinker.com announces that a new market ... Fetal Monitoring, Diagnostics and ... An overview of the ... tests. Analysis of market trends, with data ...
... -- Nutrastar International Inc. (OTCBB: NUIN; "Nutrastar" or the ... Traditional Chinese Medicine ("TCM") consumer products, today announced that ... conference call on Monday, May 16, 2011 at 8:00 ... the public pre-market on Monday, May 16, 2011. ...
Cached Medicine Technology:Reportlinker Adds Fetal Monitoring, Diagnostics and Predictive Tests 2Reportlinker Adds Fetal Monitoring, Diagnostics and Predictive Tests 3Reportlinker Adds Fetal Monitoring, Diagnostics and Predictive Tests 4Reportlinker Adds Fetal Monitoring, Diagnostics and Predictive Tests 5Reportlinker Adds Fetal Monitoring, Diagnostics and Predictive Tests 6Reportlinker Adds Fetal Monitoring, Diagnostics and Predictive Tests 7Reportlinker Adds Fetal Monitoring, Diagnostics and Predictive Tests 8Reportlinker Adds Fetal Monitoring, Diagnostics and Predictive Tests 9Reportlinker Adds Fetal Monitoring, Diagnostics and Predictive Tests 10Reportlinker Adds Fetal Monitoring, Diagnostics and Predictive Tests 11Nutrastar Provides First Quarter 2011 Financial Results Release Date and Conference Call Details 2Nutrastar Provides First Quarter 2011 Financial Results Release Date and Conference Call Details 3
These claw forceps are single-action with sturdy teeth that provide a broad grasping area to hold the gallbladder securely during removal....
This is a single-action instrument that features a spring handle....
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
Medicine Products: